From fiscal years 2015 through 2018, in the midst of a growing opioid epidemic, U.S. Customs and Border Protection (CBP), U.S. Immigration and Customs Enforcement, Transportation Security Administration, and U.S. Secret Service appropriately disciplined employees whose drug test results indicated illegal opioid use, based on their employee standards of conduct and tables of offenses and penalties. Additionally, during the same time period, components have either implemented or are taking steps to evaluate whether employees using prescription opioids can effectively conduct their duties. For example, components have established policies prohibiting the use of prescription opioids that may impact an employee’s ability to work, in addition to requiring employees to report such prescription opioid use. They have also implemented or are in the process of implementing measures to evaluate the fitness for duty of employees using prescription opioids. These policies establish consistent standards components can use to ensure they are allowing employees to use legally-prescribed opioids, while also ensuring their workforce is capable of effectively performing their duties. We made two recommendations to improve components’ oversight of illegal and prescription opioid use by employees. CBP and Secret Service concurred with the recommendations, which are both resolved and open.
Consistent with CDC guidance, most Office of Inspector General employees are currently serving the American people remotely. We are determined to keep interruptions to our operations to a minimum, and we appreciate your patience during this time.
Information and guidance about COVID-19 is available at coronavirus.gov.
- Executive SummaryReport NumberOIG-20-05Issue DateDocument FileDHS AgencyOversight AreaFiscal Year2020